Your session is about to expire
← Back to Search
Terpene
THC + Beta-Myrcene Effects on Cannabis Use
Phase 1
Waitlist Available
Led By Ryan Vandrey, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Demonstrate competency on cognitive performance measures at screening visit (e.g., PASAT score over 75)
Be between the ages of 18 and 55
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 hours
Awards & highlights
Study Summary
This trial will study the effects of inhaling b-myrcene and THC.
Who is the study for?
This trial is for adults aged 18-55 in good health with a BMI of 18-36 kg/m2. Participants must not be pregnant, nursing, or have high blood pressure; they should test negative for drugs (except cannabis) and demonstrate cognitive competency. Those using certain medications or with significant medical/psychiatric conditions are excluded.Check my eligibility
What is being tested?
The study investigates the effects of vaporized THC and Beta-Myrcene on participants compared to a placebo. It aims to understand how these substances are processed by the body and their impact when inhaled.See study design
What are the potential side effects?
Potential side effects may include changes in blood pressure, altered mental state due to THC's psychoactive properties, dizziness, dry mouth, fatigue, and possible allergic reactions to the ingredients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I passed a cognitive test with a score above 75.
Select...
I am between 18 and 55 years old.
Select...
I passed a cognitive test with a score above 75.
Select...
I am not allergic to delta 9-THC or myrcene.
Select...
I am not allergic to delta 9-THC or myrcene.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Self-reported Drug Effect as assessed by the Drug Effect Questionnaire (DEQ)
Secondary outcome measures
Self-reported "Tired/Sleepy" as assessed by the Drug Effect Questionnaire (DEQ)
Other outcome measures
Driving performance as assessed by composite drive score
Heart rate
Psychomotor performance as assessed by the Digit Symbol Substitution Task (DSST)
+2 moreTrial Design
9Treatment groups
Experimental Treatment
Placebo Group
Group I: Vaporized low beta-myrceneExperimental Treatment1 Intervention
2mg of vaporized beta-myrcene
Group II: Vaporized low THC and low beta-myrceneExperimental Treatment2 Interventions
15mg vaporized THC with 2mg vaporized beta-myrcene
Group III: Vaporized low THC and high beta-myrceneExperimental Treatment2 Interventions
15mg vaporized THC with 9mg vaporized beta-myrcene
Group IV: Vaporized low THC aloneExperimental Treatment1 Intervention
15mg of vaporized pure THC
Group V: Vaporized high beta-myrceneExperimental Treatment1 Intervention
9mg of vaporized beta-myrcene
Group VI: Vaporized high THC and low beta-myrceneExperimental Treatment2 Interventions
30mg vaporized THC with 2mg vaporized beta-myrcene
Group VII: Vaporized high THC and high beta-myrceneExperimental Treatment2 Interventions
30mg vaporized THC with 9mg vaporized beta-myrcene
Group VIII: Vaporized high THC aloneExperimental Treatment1 Intervention
30mg of vaporized pure THC
Group IX: PlaceboPlacebo Group1 Intervention
Placebo (ambient air)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
THC
2017
Completed Phase 1
~330
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
National Institute on Drug Abuse (NIDA)NIH
2,465 Previous Clinical Trials
2,618,601 Total Patients Enrolled
28 Trials studying Cannabis Use
6,125 Patients Enrolled for Cannabis Use
Johns Hopkins UniversityLead Sponsor
2,259 Previous Clinical Trials
14,820,621 Total Patients Enrolled
2 Trials studying Cannabis Use
120 Patients Enrolled for Cannabis Use
Ryan Vandrey, PhDPrincipal InvestigatorJohns Hopkins University
12 Previous Clinical Trials
553 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have anemia or I donated blood in the last 30 days.My overall health is good, as confirmed by recent medical exams and tests.I am not on medication that affects the study, except for birth control.I haven't taken any over-the-counter drugs, supplements, or vitamins in the last 14 days that could affect the study.You have not used any illegal drugs or certain prescription drugs for recreational purposes in the past three months, except for nicotine, alcohol, or caffeine.You have a history of serious medical or mental health conditions that could make it risky for you to participate in the study.I passed a cognitive test with a score above 75.I do not have serious heart rhythm problems or spasms in my blood vessels.I am between 18 and 55 years old.I passed a cognitive test with a score above 75.I am not allergic to delta 9-THC or myrcene.I am not allergic to delta 9-THC or myrcene.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: Vaporized high THC alone
- Group 3: Vaporized low THC alone
- Group 4: Vaporized low beta-myrcene
- Group 5: Vaporized high beta-myrcene
- Group 6: Vaporized low THC and low beta-myrcene
- Group 7: Vaporized low THC and high beta-myrcene
- Group 8: Vaporized high THC and low beta-myrcene
- Group 9: Vaporized high THC and high beta-myrcene
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still opportunities available for enrolment in this clinical experiment?
"At this time, clinicaltrials.gov clearly states that no new patients are being recruited for this particular trial. It began on May 1st 2023 and was last amended on November 8th 2022. However, there are more than 120 other medical studies actively recruiting participants at present."
Answered by AI
Has the Food and Drug Administration given its sanction to tetrahydrocannabinol?
"The safety rating of THC stands at 1 since the trial is currently in Phase 1 and there are limited clinical studies to support its efficacy or security."
Answered by AI
Does this trial include participants aged 25 and over?
"This trial is open to adults aged 18-55; those younger and older should refer to the 17 trials for minors, or the 48 studies meant for senior citizens."
Answered by AI
Do I have the option to partake in this experiment?
"This research study is seeking 32 candidates that have used cannabis in the past and are aged between 18-55. Those interested must be physically healthy, with a BMI of 18-36kg/m2 and blood pressure below 150mmHg (SBP) or 90 mm Hg (DBP). Additionally, participants should demonstrate competency on cognitive performance measures during screening; test negative for drugs other than cannabis at both screening visit and clinic admission; not pregnant nor nursing if female; possess no allergies to any of the ingredients used in vapor preparation; agree to written informed consent form as well as meet all other criteria set forth by researchers."
Answered by AI
Who else is applying?
What state do they live in?
Maryland
What portion of applicants met pre-screening criteria?
Met criteria
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger